Quarterly report pursuant to Section 13 or 15(d)

Basis of Presentation and Summary of Significant Accounting Policies - Narrative (Details)

v3.20.2
Basis of Presentation and Summary of Significant Accounting Policies - Narrative (Details)
1 Months Ended 3 Months Ended 6 Months Ended
Dec. 31, 2018
USD ($)
Jun. 30, 2020
USD ($)
position
$ / shares
shares
Jun. 30, 2019
USD ($)
shares
Jun. 30, 2020
USD ($)
position
$ / shares
shares
Jun. 30, 2019
USD ($)
shares
Jan. 01, 2020
USD ($)
Dec. 31, 2019
USD ($)
Property, Plant and Equipment [Line Items]              
Accounting Standards Update       us-gaap:AccountingStandardsUpdate201613Member      
Revenue recognized from milestone method revenue   $ 2,000,000.0 $ 2,700,000 $ 2,400,000 $ 4,100,000    
Fair value of equity securities   $ 8,816,000   $ 8,816,000     $ 9,910,000
Number of positions in an unrealized loss position | position   7   7      
Credit losses related to available-for-sale debt securities   $ 0   $ 0      
Additional allowance for credit losses recorded related to COVID-19   100,000   $ 300,000      
Allowance for credit loss           $ 5,500,000  
Increase (decrease) to allowance for credit loss during period   $ 500,000          
Potentially dilutive shares excluded from calculation due to anti-dilutive effect (shares) | shares   7,832,000 7,457,000 8,988,000 7,243,000    
Warrants              
Property, Plant and Equipment [Line Items]              
Fair value of equity securities   $ 177,000   $ 177,000     125,000
Warrants | Short-term Investments              
Property, Plant and Equipment [Line Items]              
Fair value of equity securities   $ 8,800,000   $ 8,800,000     9,900,000
Share-based Compensation              
Property, Plant and Equipment [Line Items]              
Potentially dilutive shares excluded from calculation due to anti-dilutive effect (shares) | shares     800,000 600,000      
Adjustment              
Property, Plant and Equipment [Line Items]              
Cumulative-effect adjustment from adoption of ASU 2016-13, net of tax             (5,167,000)
Viking Therapeutics, Inc.              
Property, Plant and Equipment [Line Items]              
Warrant exercise price (USD per share) | $ / shares   $ 1.50   $ 1.50      
Viking Therapeutics, Inc. | Common Stock | Short-term Investments              
Property, Plant and Equipment [Line Items]              
Fair value of equity securities   $ 43,500,000   $ 43,500,000     48,400,000
Palvella              
Property, Plant and Equipment [Line Items]              
Revenue recognized from milestone method revenue   3,000,000.0   $ 3,000,000.0      
Royalty Agreements | Aziyo              
Property, Plant and Equipment [Line Items]              
Effective interest rate for forecasted cash flows (as a percent)       23.00%      
Commercial license rights              
Property, Plant and Equipment [Line Items]              
Up-front payment   38,298,000   $ 38,298,000     38,298,000
Commercial license rights | Palvella              
Property, Plant and Equipment [Line Items]              
Contract asset $ 8,000,000.0            
Up-front payment $ 10,000,000.0 $ 10,000,000   $ 10,000,000     $ 10,000,000
Minimum | Royalty Agreements | Palvella              
Property, Plant and Equipment [Line Items]              
Tiered royalty rate (as a percent) 5.00%            
Maximum | Viking Therapeutics, Inc.              
Property, Plant and Equipment [Line Items]              
Outstanding warrants to purchase shares of Viking's common stock (shares) | shares   1,500,000   1,500,000      
Maximum | Royalty Agreements | Palvella              
Property, Plant and Equipment [Line Items]              
Tiered royalty rate (as a percent) 9.80%